MDS Nordion to expand Belgian FDG facility

Radioisotope developer MDS Nordion of Kanata, Ontario, is investing $5.8 million (U.S.) to expand its production facility in Fleurus, Belgium, to meet the demand for the imaging agent fluorine-18 fluorodeoxyglucose (F-18 FDG).

MDS Nordion markets FDG under the name Glucotrace, with production as part of a joint venture with the University of Liège in Belgium.

First production of Glucotrace from the new facility is expected to begin in mid-2008. The firm plans to serve more customers in France, Belgium, the Netherlands, and Luxembourg with its increased production.

By AuntMinnie.com staff writers
March 22, 2007

Related Reading

MDS names Prince as CFO, February 20, 2007

MDS Nordion opens European TheraSphere centers, February 8, 2007

MDS Nordion shows Q4 revenue downturn, year-end upturn, December 14, 2006

MDS sells diagnostics unit, October 5, 2006

MDS Nordion gets FDA OK for TheraSphere clinical trials, September 26, 2006

Copyright © 2007 AuntMinnie.com

Page 1 of 1262
Next Page